Press release from Companies
Published: 2024-03-22 10:04:35
As outlined in the text titled "Lessons learned from five years of venture development," published in March 2024, Katalysen Ventures AB (publ) ("Katalysen", the "Company") has amassed significant venture development data and experience since the company’s inception. Drawing upon these insights, along with the execution of two "proof-of-concept" transactions during the winter of 2023-2024, Katalysen is now formally introducing a new investment framework to the Company’s venture developer platform. For the full version of this text, visit www.katalysen.com.
This new framework, known as the Venture Targeter Framework ("VTF"), signifies Katalysen's transition into a next phase of venture development. With VTF, employing a smaller in-house team, the Company is capable of delivering superior expertise, generating increased value within a shorter timeframe (3 months instead of 3 years), and sustaining its status as a highly agile investor adept at capitalizing on short- and medium-term market opportunities.
Phase two and VTF in short:
As of March 2024, Katalysen has successfully executed two transactions using VTF: Venture Targeter 1 (VT1), investing in Swedish biotech venture QuTEM, and Venture Targeter 3 (VT3), investing in German healthtech venture S4DX. The sequential numbering of these transactions offers a clue to our simultaneous involvement in multiple projects.
VT3 and its investment into German healthtech venture S4DX was completed in March 2024, and as such it is too early to fully evaluate the venture’s progress following the transaction. However, the following is certain:
Katalysen is excited to continue to invest alongside Katalysen’s exceptional network, and the Company invites all shareholders to get in touch to discuss potential VTF cases where mutual value creation is possible.
For more information on Katalysen Ventures, please contact:
CEO Peter Almberg
Phone: +46 76 860 37 00
E-mail: contact@katalysen.com
Web: www.katalysen.com